Slide 1: Webinar Presentation – Australian Shareholders' Association
For immediate release 29 May 2020 Webinar Presentation – Australian Shareholders’ Association Please find attached a presentation used for a lunchtime Webinar presentation with the Australian Shareholder’s Association today. This presentation is provided to the ASX for the information of all CSL’s s
Slide 2: CSL Limited: Update on operations and future growth
CSL Limited Update on operations and future growth David Lamont, CFO ASA Webinar, 29 May 2020
Slide 3: Participating in the Webinar
Participating in the Webinar Listen in through computer audio. Headset recommended. or Select Phone Call to see the number to call, Access Code and PIN Type your questions or just say hello here. Attendee Control Panel
Slide 4: Legal Notice
LEGAL NOTICE Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all o
Slide 5: Overview
Overview CSL is a leading global biotech company that develops and delivers innovative biotherapies and influenza vaccines that save lives and help people with life-threatening medical conditions live full lives 60+ Countries of operations around the world US$8.5bn+ inrevenue annual (FY19) 8 Manufac
Slide 6: CSL Today
CSL Today Current 3rd Largest Global Biotech Industry Themes 1 Global #1 in plasma therapies • $30 billion industry Plasma Supply Growth 2 Global #2 in influenza vaccines • $6 billion industry Robust Ig demand Strong Market Position • Revenue FY19 ~$8.5bn Influenza Vaccine • 8 major manufacturing si
Slide 7: Values and Strategy
Values and Strategy • Technology • Process Improvement • Operational Excellence • Capital Project Execution • Products Growth Platforms: • Delivery • Plasma • Services • Recombinants Strategic • Technology • Cell & Gene Therapy • Influenza Vaccines Overview • Immunology & Neurology • Connected • Hae
Slide 8: Business Highlights
Business Highlights Strong Balanced Executing to Ig Growth well Expanding Compelling Business Regional Plan on New Above Market Market real-world Performance Growth Launches Presence effectiveness through New influenza Affiliates vaccine data 7 | Driven by Our Promise™
Slide 9: Strong and Consistent Revenue Growth
Strong and Consistent Revenue Growth US$B 10 8 CAGR 9% 6 4 2 0 8 | Driven by Our Promise™
Slide 10: Shareholder Returns
Shareholder Returns US US$ Earnings Per Share cents Dividends 200 5 4 160 EPS 3 120 2 80 1 40 0 0 9 | Driven by Our Promise™
Slide 11: Shareholder Value
Shareholder Value A$ A$B 350 Share Price 140 Market Capitalisation 300 27%pa 120 5 year CAGR 250 100 200 80 150 60 100 40 50 20 0 0 1996 2002 2008 2014 2020 CSL CBA BHP WBC NAB WES ANZ WOW TCL MQG 10 | Driven by Our Promise™
Slide 12: Global & Diverse Revenue Base
Global & Diverse Revenue Base FY19 Revenue US$8.5B North America Immunoglobulins 49% $3,543m Specialty $1,572m Seqirus Australia Europe $1,196m 8% 26% Haemophilia $1051m ROW 6% Asia Albumin 11% $1,018m 11 | Driven by Our Promise™
Slide 13: 1H20 Performance
1H20 Performance A strong half year for CSL with revenue up 11%1 and net profit after tax up 11%1 reflecting: • Strong growth in CSL BEHRING SEQIRUS immunoglobulin portfolio • PRIVIGEN® +28%1 • Seasonal influenza +16%1 • Transition to own distribution model in China progressing • HIZENTRA® +37%1 • F
Slide 14: 1H20 Financial Highlights
1H 20 Financial Highlights Half year ended Dec 1H19 1H20 1H20 Change US$ Millions Reported Reported at CC1 % Total Revenue 4,505 4,911 4,980 11%1 Gross Profit 2,623 2,842 2,891 10%1 GP margin 58.2% 57.9% 58.0% EBIT 1,553 1,632 1,679 8%1 NPAT 1,161 1,248 1,292 11%1 Cashflow from Operations 535 1,245
Slide 15: Commitment to Research and Development
Commitment to Research and Development R&D Spend New R&D Facilities US$m Bio21 Institute, Melbourne 900 832 • ~ 4100m2 of lab and office space • Parkville precinct 750 702 667 614 • Melbourne University, MRI’s 600 • 4 major teaching hospitals 466 463 450 SITEM1, Bern 300 • 2000m2 of lab and office s
Slide 16: R&D Highlights
R&D Highlights Immunology • HIZENTRA® granted Orphan Drug Exclusivity for CIDP • HIZENTRA® Dermatomyositis (DM) Phase III Study initiated and Neurology • Garadacimab (Anti-FXIIa) in Hereditary Angioedema (HAE) Phase II double blind period complete Haematology • CSL200 (CAL-H) in Sickle Cell Disease
Slide 17: COVID-19 Update
COVID-19 Update Response Employees • Primary objective is to ensure safety and • Health and welfare of staff are of primary wellbeing of our staff, donors and continuity of importance to CSL supply of medicines to patients • Wherever possible, staff are strongly encouraged • Business continuity plan
Slide 18: Focused COVID-19 Response
Focused COVID-19 Response Prevention Treatment severity Population General public At-risk healthcare workers and infected patients Therapeutic Options * Vaccines * Hyperimmunes * Monoclonal antibodies Polyclonal antibodies CSL Assets & Adjuvant technology Process development CSL312; CSL324 Capabilit
Slide 19: Growth Catalysts Outperformance Drivers
Growth Catalysts Outperformance PLASMA PROTEINS Drivers • Ongoing robust demand • Commercialization of 5 global product launches • Grow China business • R&D pipeline - CVD, Fc Multimer, transplant, gene therapy INNOVATION INFLUENZA • Product differentiation – FLUCELVAX® • Sales shifting towards FLUA
Slide 20: CSL Limited
CSL Limited CSL